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Abstract
Extracellular vesicles are defined as a heterogeneous group of vesicles that are released by prokaryotic to higher
eukaryotic cells and by plant cells in an evolutionary conserved manner. The significance of these vesicles lies in
their capacity to transfer selected cargo composed of proteins, lipids and nucleic acids to both recipient and parent
cells and to influence various physiological and pathological functions. Microorganisms such as parasites, fungi and
protozoa and even single cell organisms such as bacteria generate extracellular vesicles. In addition, several viruses
have evolved strategies to hijack the extracellular vesicles for egress or to alter the surrounding environment. The
thesis of this article is that: a) during HSV-1 infection vesicles are delivered from infected to uninfected cells that
influence the infection; b) the cargo of these vesicles consists of viral and host transcripts (mRNAs, miRNAs and
non-coding RNAs) and proteins including innate immune components, such as STING; and c) the viral vesicles carry
the tetraspanins CD9, CD63 and CD81, which are considered as markers of exosomes. Therefore, we assume that
the STING-carrying vesicles, produced during HSV-1 infection, are reminiscent to exosomes. The presumed functions
of the exosomes released from HSV-1 infected cells include priming the recipient cells and accelerating antiviral
responses to control the dissemination of the virus. This may be one strategy used by the virus to prevent the
elimination by the host and establish persistent infection. In conclusion, the modification of the cargo of exosomes
appears to be part of the strategy that HSV-1 has evolved to establish lifelong persistent infections into the human
body to ensure successful dissemination between individuals.
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Background
Extracellular vesicles
Cells have developed different mechanisms for intercel-
lular communication. Three pathways that have been
studied include: a) cell to cell contact; b) secretion of
molecules; and c) extracellular vesicles (EVs). This last
mechanism was described for the first time in 1983 by
two groups [1–3]. Since the discovery of EVs a wealth of
information has underscored their impact in normal and
pathological processes.
Extracellular vesicles (EVs) is a broad term that
describes a heterogeneous group of vesicles released
from the cells [4–7]. Based on their origin they are
broadly classified into 3 main groups: a) microvesicles/
microparticles/ectosomes that are produced from the
plasma membrane by outward budding and fission and
their size ranges from 100 to 1000 nm; b) apoptotic
bodies that are released as blebs from cells undergoing
apoptosis and they range from 1000 to 5000 nm; and c)
exosomes that are formed by invagination and inward
budding of vesicles in the lumen of early endosome,
resulting in the formation of multivesicular bodies
(MVBs), also called multivesicular endosomes (MVEs)
[4, 5]. The MVBs fuse with the plasma membrane
releasing the exosomes to the extracellular space. The
size of the exosomes ranges from 40 to 100 nm. The
major biogenesis pathway of the intraluminal vesicles
involves the endosomal sorting complex required for
transport (ESCRT) machinery [6–10]. The ESCRT-0
complex and its partner Hrs are involved in the seques-
tration of ubiquitinated cargo but also in the recruitment
of the ESCRT-I complex by interacting with TSG101.
ESCRT-I and –II complexes appear to be responsible for
the budding and ESCRT-III for the scission of the
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vesicles in the lumen of the endosomes [11–14]. The
MVBs can either fuse with lysosomes ending in the
degradation of their content, or follow a secretory path-
way leading to the release of the exosomes [15]. The
mechanism underlying the fate of MVBs is not yet fully
understood, but involves in part the lipid composition of
exosomes [4, 9, 15]. MVBs enriched in cholesterol are
more likely to follow the exocytic pathway, whereas
cholesterol-poor MVBs are targeted to the lysosomes
[15]. Ceramide appears to trigger the budding of exo-
somes into MVBs [16]. Moreover, lysobisphosphatidic
acid is enriched in endosomes targeted for degradation
but absent from exosomes.
Initially, EVs were viewed as means for cells to dispose
of unwanted components. However, in the intervening
decade this view has largely changed and it is clear that
the cargo of the EVs and the type of recipient cells deter-
mine their function [4, 5, 17]. The cargo of the EVs
consists of nucleic acids, proteins and lipids. The nucleic
acids in EVs are mainly miRNAs, mRNAs and non-
coding RNAs [18–24]. These nucleic acids are not
randomly incorporated into EVs but rather are preferen-
tially packaged [25, 26]. Moreover, the RNAs in EVs do
not reflect the quantity of RNAs in the cells where they
originated. Strikingly, the transcripts are intact and they
can be translated inside the recipient cells to influence
gene expression [25, 26]. For this reason the EVs have
emerged as carriers of genetic information that are able
to modify the pattern of gene expression in recipient
cells. The proteins found in EVs are mainly from endo-
somes, the plasma membrane and the cytosol. Proteins
from organelles such as nucleus, mitochondria, endo-
plasmic reticulum and the Golgi complex are largely
absent. These observations highlight the specificity of
the cargo of these vesicles [17]. Lipids, particularly
sphingomyelin, cholesterol and hexosylceramides are
enriched in EVs at the expense of phosphatidylcho-
line and phosphatidylethanolamine. Both saturated
and monounsaturated fatty acids are also enriched in
EVs [6, 16, 27–31].
With respect to the functions of EVs, organisms from
different domains of life secrete extracellular vesicles to
disseminate information to remote sites from the place
of their origin, influencing the surrounding microenvir-
onment through a paracrine mechanism, or altering
physiological functions through long distance targeting
via the systemic circulation [5]. The composition of EVs
is subjected to dramatic changes following alterations in
the extracellular environment or different physiological
or differentiation stages of the secreting cells. For
example, inflammatory signals or activation of innate
immunity strongly affect the composition of EVs
released by immune cells [32]. In hypoxic conditions
of some tumors, the acidic environment or expression
of oncogenes radically changes the cargo of the EVs.
Moreover, exosomes may contribute to intercellular
exchange and spread of prions and misfolded proteins
associated with neurodegenerative diseases [33–35].
Based on these properties, EVs are exploited today as
diagnostic tools especially in cancer to determine the
status of the tumor or its origin, and as vehicles for
the delivery of therapeutic small interfering RNAs
(siRNAs) [36].
The extracellular vesicles during viral infections
Many viruses have evolved strategies that rely on the
properties and functions of the extracellular vesicles to
evade the host [5, 37]. The exosomes released during
HIV-1 infection were the first to be studied [37–39]. In
2006, the Trojan exosome hypothesis proposed that
retroviruses hijack the exosome biogenesis pathway to
release infectious particles encapsulated into exosomal
vesicles. Pathways of exosome uptake are utilized for a
viral receptor-independent, envelope-independent mode
of infection [40]. For example, exosomes derived from
dendritic cells, can carry HIV-1 virions that escaped
phagolytic and proteasomal degradation. As dendritic
cells migrate to the lymph nodes, to present pathogen-
derived epitopes to CD4+ T or CD8+ T lymphocytes,
they can transfer HIV-1 to T cells through exosomes,
without de novo infection [40, 41]. However, the nature
of vesicles delivering HIV-1 today is debatable since the
virus budding sites coincide with sites of microvesicle
biogenesis. Unspliced HIV-1 RNA species but not
single- or double-spliced HIV-1 RNAs have been found
in exosomes derived either from HIV-1 infected cells or
patients [42]. The viral transactivating response element
(TAR), which enhances viral replication in recipient
cells, is also present in exosomes [43]. Several viral
miRNAs including vmiR88, vmiR99 and vmiR-TAR have
been detected in exosomes secreted from HIV-1 infected
cultures, or isolated from sera of patients [44]. The
exosomal vmiR-TAR prevents apoptosis in recipient cells
and thereby promotes the infection, whereas the other
two miRNAs stimulate release of pro-inflammatory
cytokines, such as TNF-α, from recipient macrophages,
which may contribute to AIDS pathogenesis [44]. Besides
RNA transcripts, many proteins have been detected in
EVs derived from HIV-1 infected cells, among them the
HIV-1 co-receptors CCR5 and CXCR4, which upon
delivery to co-receptor null cells allow HIV-1 entry
[45, 46]. This is may be a strategy of HIV-1 to modify
its tropism in an otherwise non-permissive background.
Additionally, APOBEC3G (A3G), a cytidine deaminase,
which is part of the innate host defense system against
HIV-1 and other retroviruses, was found in exosomes
[47, 48]. Exosomal A3G could confer resistance to
both Vif-defective and wild type HIV-1 in exosome
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recipient cells, suggesting that the restriction was through
a non-enzymatic mechanism [49, 50]. Several studies
point to the existence of editing-independent activities of
A3G that may contribute to its antiviral function [51, 52].
The growing list of proteins found in the exosomes
released from HIV-1 infected cells include CD86, CD45
and MHC class II, which may help suppressing immune
responses thereby facilitating the virus replication [53].
HIV-1 proteins Gag and Nef have also been shown to
be packaged in exosomes [37, 38]. HIV-1 Nef is one of
the earliest and most abundantly expressed proteins of
HIV-1. Nef was found in exosomes of infected cells in
cultures and also in plasma-derived exosomes from
patients [38, 54]. Exosomal Nef activates resting CD4+ T
cells, rendering them permissive to HIV-1 infection, and
this way it stimulates the spread of the virus [38, 55].
Nef also increases the exosome production in HIV-1
infected or Nef-transduced cells [56]. In addition, by
interacting with vesicular sorting and trafficking path-
ways it directs MHC-I, CD4 and possible other proteins
to MVB for lysosomal degradation, thereby promoting
virus replication [57, 58]. Finally, Nef can modulate the
miRNA composition of exosomes [59].
Other RNA viruses also hijack the exosomes [37, 39,
60–65]. The exosomes derived from the hepatocytes or
from the sera of the hepatitis C virus (HCV) infected
patients carry the single-stranded, positive-sense viral
RNA genome, and mediate receptor-independent HCV
transmission to permissive cells, leading to productive
infection [39, 61–65]. The replication competent, negative-
stranded viral RNA is also detected in the exosomes [66].
The tetraspanin CD81 is an integral membrane protein and
exosome marker, which also serves as a viral entry receptor
for HCV. It forms a complex with the viral envelope
protein E2 and facilitates its cellular and intercellular
trafficking [67, 68]. The HCV genome and the CD81-
E2 complex exit cells inside exosomes where they
circulate and exploit the fusogenic capabilities of
these vesicles to infect naïve cells. Neutralizing anti-
bodies do not interfere with this mechanism of virus
spread [67]. Another example is the non-enveloped
hepatitis A virus (HAV), whose nucleocapsids were
found into vesicles derived from endosomal compart-
ments [60, 69]. This cloaked virus not only was fully
infectious but was totally protected from neutralizing
antibodies [60, 69]. The virus, via the interaction of
the capsid protein VP2 with Alix and the contribution
of the VPS4B, two ESCRT-III components, utilizes the
exosomes biogenesis machinery to release non-enveloped
HAV [60, 69]. Occasionally HAV hijacks membranes
and encapsulated virions are released, in an Alix and
VPS4B –dependent mechanism [60]. In patients with
acute hepatitis A infection, the encapsulated virions were
shown to be the dominant form of HAV detected in
serum [60, 70]. Antibodies directed against the viral capsid
effectively neutralize non-enveloped HAV but did not
affect enveloped virus infection [60]. It is possible that the
encapsidation of HAV into exosomes is a strategy of the
virus to disseminate while escaping immune detection.
Human tumor viruses such as the Epstein-Barr virus
(EBV) utilize exosomes to influence the intercellular
communication [37, 71]. EBV virus rapidly establishes
latent infection in its preferred target cells, the human B
lymphocytes, and for this reason the exosomes from
these lymphocytes have been most studied. During
latency only few viral genes are expressed. The latent
membrane protein 1 (LMP1) of EBV is considered the
major oncogene and is expressed in multiple human
malignancies. LMP1 functions as a constitutive active
member of the tumor necrosis factor receptor family,
inducing genes that are involved in pro-inflammatory
responses, apoptosis, cell proliferation, migration and
cell cycle progression [72, 73]. Exosomes released from
nasopharyngeal carcinoma (NPC) cells positive for EBV,
in which the latency II program of the virus is expressed,
contain LMP1 [71], viral miRNAs and signal transduc-
tion molecules, such as the epidermal growth factor
receptor EGFR [71], galectin-9 [74], fibroblast growth
factor (FGF-2) [75], deoxyuridinetriphosphatase (dUTPase)
[76]. These exosomes manipulate the tumor microenvir-
onment to enhance tumor progression and alleviate
immune responses in tumor cells.
Similar to EBV, the human Kaposi sarcoma virus
(KHSV) is associated with multiple lymphomas. Both
viruses alter the content of exosomes to modulate cell
death and protein synthesis. Analysis of the cargo of
exosomes derived from EBV or KHSV-latently infected
B lymphocytes demonstrated that approximately one
third of the proteins found in the exosomes were unique
to the latently infected cells [77]. The functions of these
proteins are associated with cancer, cell survival, cell
death and disease [77]. Exosomes produced from KSHV-
infected primary effusion lymphoma (PEL) cells are
highly enriched with enzymes from the glycolytic path-
way and at least in B cells they promote glycolysis [77].
These enzymes include pyruvate kinase, enolase, glycer-
aldehyde dehydrogenase, phosphoglucose isomerase and
others. Therefore, a legitimate hypothesis is that exo-
somal transfer of glycolytic enzymes could enhance
glycolysis in recipient cells [78, 79]. In addition, the
ribosomal subunits 40S and 60S and several translation
initiation factors were found to be increased in KSHV–
infected PEL cells, which are most likely through the
function of viral proteins K1 and viral G protein that are
known to modulate the cellular protein synthesis
machinery [77]. Although histones have been shown to
be present is exosomes from different cell types, the exo-
somes from KSHV-infected PEL cells show a preferential
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increase in histones H1, H2A, H2B, H3 and H4 [77].
The KSHV-infected PEL exosomes also influence adhe-
rens junctions of epithelial cells and thus contribute to
viral persistence and pathogenesis [77]. Overall, the exo-
somes produced from KSHV-infected lymphomas ap-
pear to exacerbate disease progression and pathogenesis.
An intriguing observation was that the nuclear DNA
sensor IFI16 is packaged in exosomes and delivered from
latently infected KHSV cells to uninfected cells. Activa-
tion of IFI16 leads to pro-inflammatory and IFN re-
sponses. IFI16 is restriction factor for HSV-1 and 2 and
HCMV [80–83]. How exosomal IFI16 could impact im-
munity to herpes viruses remains elusive.
With respect to the exosomes produced during the
lytic cycle of gamma-herpesviruses, recent studies dem-
onstrated that during EBV infection a pre-latent phase
precedes the stable latent phase [84]. During the pre-
latent phase the virus expresses a subset of immediate-
early, early and latent genes, including viral homologues
of the anti-apoptotic Bcl-2 family members, the viral
interleukin (vIL-10) and BZLF1 that secure the initial
success of the EBV infection by blunting immunity and
facilitating latency establishment [84, 85]. Additionally,
during the pre-latent phase of the infection the EBV par-
ticles and the non-viral vesicles that are released from
the cells contain viral RNAs of different classes that are
delivered to target cells. The packaged viral mRNAs are
intact, they are translated in the recipient cells and along
with the non-coding RNAs induce viral and cellular
genes that potentially modify pathways related to innate
and adaptive immune responses [84, 85]. For instance,
translation of delivered BZLF1 transcripts could activate
resting cells and induce cell-cycle entry, translation of
BHRF1 and BALF1 delivered transcripts might protect
the infected cells from cell death, delivered miRNAs
might control detrimental antiviral responses of the
newly infected cells and translation of secreted viral IL-
10 mRNAs most likely protect EBV-infected cells from
antiviral responses of the innate and adaptive immune
system [86–88]. Additionally, the immunoevasins (vIL-
10, BGLF5, BNLF2a), expressed into the recipient cells
following delivery of their mRNAs within vesicles that
are released from the pre-latent EBV infected cells,
could protect the newly infected cells from antigen-spe-
cific T-cell responses that might otherwise eliminate
the newly infected cells before latency can be estab-
lished [84, 85].
Taken together, extracellular vesicles are released dur-
ing the productive and the latent stages of gamma-
herpesviruses infection but the cargo of these vesicles is
substantially different. During the productive cycle the
cargo contributes to the success of infection, it primes
the cells for persistent infection and prevents the elimin-
ation of the virus by the host’s immune system, while
the cargo delivered from latently infected cells contrib-
utes to virus persistence.
Other herpesviruses modulate the cargo of exosomes.
Herpes simplex virus glycoprotein B expressed during
the lytic cycle perturbs the endosomal sorting and
trafficking of HLA-DR (DR) receptors [89]. Glycoprotein
B binds to the DR groove and inhibits the association of
peptides to the DR heterodimer [89]. Both proteins co-
localize in MVBs and together with CD63 the three
proteins are released into the supernatant of infected
cells, presumably through the exosomal pathway [89].
The delivery of this complex to recipient cells could
modulate immune responses to viral antigens. Human
herpes virus 6 (HHV-6) induces formation of MVBs and
both viral glycoproteins gB and gM were found in the
intraluminal vesicles [90]. Similar to HSV, DR and CD63
along with the glycoproteins gB of HHV-6 are packaged
in exosomes and delivered to target cells [89].
The emerging roles of different types of extracellular
vesicles and particularly of exosomes in infectious diseases
could provide information about pathogens and their
strategies for dissemination.
The extracellular vesicles in herpes simplex virus-infected
cells
During herpes simplex virus infection different kind of
vesicles appear to be released extracellularly. Szilagyi
and Cunningham reported that in addition to the
virions, also known as H (Heavy)-particles, other parti-
cles named L (Light)-particles are released [91]. Micro-
vesicles, is an alternative term utilized frequently for the
L-particles although with the current knowledge on EVs
the term might not be accurate. The L-particles are
composed of virus envelope and tegument proteins but
they lack viral genome and viral capsid proteins. The
L-particles cover a wide range of sizes and often con-
tain inclusion vesicles of variable size and number
[91–93]. Although the L-particles are non-infectious
they were shown to facilitate the HSV-1 infection, at least
in cell cultures, most likely by delivering viral proteins
such as ICP0 and ICP4 to the target cells and possibly
cellular factors that are needed for virus replication and
suppression of antiviral responses [91–94].
Apoptotic bodies have been reported on certain occa-
sions during herpes simplex virus infection although
several HSV genes are known to block apoptosis. Thus,
neonatal neutrophils on infection break up into mul-
tiple apoptotic bodies that contain live virus and they
may facilitate the spread of HSV as the apoptotic bodies
are engulfed by macrophages [95]. Apoptotic bodies
might also be released by neuronal cells undergoing
apoptosis during HSV infection [96–98]. The size of
apoptotic bodies as reported earlier ranges between
1000 and 5000 nm.
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From this point forward the focus of the review
will be on extracellular vesicles with a size range
between 50 and 110 nm that are released from the
HSV infected cells and they have properties similar
to exosomes, that is, they carry the exosomal markers
CD63, CD9 and CD81 and are smaller than apoptotic
bodies or microvesicles. The concept that extracellular
vesicles are released upon infection having properties
similar to exosomes is based on the observations
discussed below:
STING (STimulator of Interferon Genes) is a sensor
of DNA in the cytoplasm, which has functions hostile to
the virus in normal cells and in mice that impede virus
replication and dissemination [99–101]. However, in a
number of cancer derived cell lines such as human
cervical carcinoma (HeLa) and human epithelial (HEp-2)
STING was protected from elimination by the wild type
HSV-1. This conclusion emanated from the observation
that STING was rapidly eliminated from these cells
following infection by HSV mutants impaired in the
execution of late viral functions such as the ICP0 E3
ligase activity and the ICP0- null mutant, a Us3
kinase-deficient mutant and the ΔICP4 replication-
deficient mutant [102]. These data suggested that the
functions of ICP0 and Us3 were required to protect
STING from elimination [102]. Moreover, experiments
that assessed the growth of the wild type HSV-1 and
the ICP0 null- mutant in normal immortalized (hu-
man embryonic lung fibroblasts; HEL) and cancer
cells (epithelial HEp-2) depleted of STING, demon-
strated that although STING was detrimental to both
viruses in the normal cells, it was required for
optimum replication for both viruses in the cancer
cells [102]. Taken together, these data suggested that
STING, under certain conditions, might be utilized by
HSV-1 [102].
A clue as to what additional functions might STING
perform during HSV-1 infection emerged from the ob-
servation that in Vero cells (African green monkey
kidney epithelial cells) the endogenous level of STING
was very low. Following exposure to different doses of
the wild type virus, STING was detectable in infected
cells as soon as 30 minutes post-inoculation and reached
a plateau at two hours post-exposure where it remained
stable up to18 h post-inoculation [103]. The accumula-
tion of STING in Vero cells was proportional to the
dose of the virus and was not related to changes in the
abundance of STING transcripts, as it remained stable
through the course of the infection [103]. Further, inhib-
ition of protein synthesis did not alter the accumulation
of STING in HSV-1-infected Vero cells [103]. These
data suggested that accumulation of STING in Vero
cells was due to the virus inoculum and not due to
stimulation of its gene expression.
Indeed, HSV-1 virions purified through a dextran-10
gradient, as described before, were found to contain
both the monomeric and a dimeric forms of STING
[103]. This observation raised two possibilities, either
that STING was incorporated in HSV-1 virions or that it
was present in separate structures co-purifying with the
virions. Several experiments were designed to address
this issue. First, immunoprecipitation reactions with the
STING antibody were carried out using dextran-10
gradient purified virions. This approach yielded negative
results as STING remained in the supernatant of the
reaction along with virion components. Two possible
scenarios could explain these results, either STING was
indeed incorporated into HSV-1 virions, or the STING
epitope, in the structures where STING was integrated,
was not accessible to the antibody and as a consequence
the protein remained in the supernatant. To distinguish
between these two possibilities a similar immunoprecipi-
tation reaction was carried out using an antibody against
the tetraspanin CD9. CD9 is a common marker of the
exosomes and it forms heterooligomers with other mem-
bers of the tetraspanin family, such as CD63, another
exosomal marker. The results of this reaction indicated
that STING was in structures separate than the virions, as
the majority of STING co-immunoprecipitated with CD9,
while the virion components remained in the supernatant
[103]. To verify the above results, the presumed virions/
exosomes mixture was incubated with antibody against
the viral glycoprotein gD, to neutralize the virus, and
subsequently the mixture was added to Vero cells, whose
endogenous STING is negligible. The rationale was that
the gD antibody would block viral entry, while the fate of
STING was expected to be independent of gD. Indeed,
the neutralized virus could not enter the cells and viral
gene expression was not detected. However STING was
delivered in Vero cells, in the presence of the neutralizing
gD antibody, even when protein synthesis was blocked by
the addition of cycloheximide [103]. These data supported
the observation that STING was not incorporated in
HSV-1 virions and further demonstrated that STING
entered the cells via a mechanism independent of the viral
entry. As an alternative approach, the release of STING
and CD9 was monitored in the supernatant of cultures
infected with a HSV-1 ΔUL18 mutant that is defective in
assembly. UL18 is essential for capsid assembly, and in its
absence virion formation does not occur [104]. UL18 is
not required for viral gene expression or the virus replica-
tion. The assumption was that if STING was in non-
virion structures, its release in the supernatant should not
be affected. Indeed, this experiment demonstrated that
both STING and CD9 were in the culture supernatant of
the ΔUL18 mutant infected cells despite the absence of
virions. Although there might be differences in the num-
ber and molecular composition of the STING-carrying
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vesicles in the supernatant, cells inoculated with this
mutant provided useful information with respect to
the presence of STING in exosomes.
It worth mentioning that the Vero cell line which
expresses low levels of STING, was identified as a
useful system to study delivery of the EVs carrying
STING. Interestingly, the level of CD9 (an marker for
exosomes) in Vero cells is remarkably low compared to
other cell lines, which may be indicative to the number
and/or type of vesicles released from these cells.
The previous data not only supported that STING was
released in higher-ordered structures in the supernatant
of the infected cultures but provided some clues about
structural characteristics of these structures. These in-
cluded that: a) the vesicles could be delivered to target
cells, as STING from the virus inoculum was delivered
into the recipient cells exposed to the virus; b) the
optimal time for delivery was approximately two hours
as the levels of STING in the recipient cells gradually
increased for the first two hours following exposure; c)
the HSV-1 glycoprotein gD was not required for the
STING-carrying structures to enter the target cells; d)
protein synthesis was not required for their entry; and e)
in dextran-10 density gradients, HSV-1 virions and the
structures carrying STING co-purified. As it will be
discussed later, co-fractionation in some density gradi-
ents is most likely due to co-aggregation during high
speed sedimentation.
STING has four transmembrane regions and a carboxy-
terminal domain, and has been classified as an endo-
plasmic reticulum (ER) protein, which may associates
with mitochondria-associated ER membranes (MAM)
at the interface between the mitochondrion and the
ER [105–107]. Following activation, STING appears to
re-localize from ER to perinuclear vesicles [105–107].
On infection of a HEp-2 cell line stably expressing
human STING, the protein was found in globular
structures in the perinuclear region and at the poles
of the cells. Tetraspanins CD63 and CD81 perfectly
co-localized with STING in the globular structures
[Kalamvoki et al, unpublished data]. CD63, the first
characterized tetraspanin, is mainly associated with
membranes of intracellular vesicles and is abundantly
present in late endosomes and lysosomes [4, 108, 109].
CD63 is enriched in the intraluminal vesicles of
multivesicular bodies (MVBs), which are secreted as
exosomes through fusion of the MVBs with the
plasma membrane [109]. Localization of CD63 at the
plasma membrane has been described in clusters
called tetraspanin-enriched microdomains [108–110].
Similarly, CD81 is another marker of exosomes and
an integral component of the plasma membrane
found in focal adhesions and occasionally immunological
synapses [4, 108].
Taken together, these data suggest that STING is pack-
aged in extracellular vesicles during HSV-1 infection
reminiscent to exosomes. These vesicles will be referred
as “HSV-1 exosomes or viral exosomes” as their cargo
consists not only of host but also viral factors. Below we
will describe the most effective approach to efficiently
separate the viral exosomes from HSV virions.
The challenge of separating the HSV-1 exosomes from
herpes simplex virus 1 particles
The observation was made that HSV stocks were either
enriched or depleted of the STING-carrying vesicles
depending on the cell line in which the viral stock was
produced [103]. Viral stocks prepared in HEp-2 cells
were enriched in STING/CD9-containing vesicles while
stocks prepared in Vero cells were largely devoid of
STING/CD9-containing vesicles [103]. Thus, the lack of
purity and the heterogeneity of the virus inoculum is
dependent on the cell line used to propagate the viral
stock and should be taken into consideration as they
could account for differences in host responses [103].
Several different approaches have been used in an attempt
to separate the HSV-1 virions from the STING-carrying
vesicles. We will discuss the results of each approach below.
The first approach was based on immunoaffinity. It
involved differential centrifugation of the culture super-
natants to clarify cells debris and nuclei, followed by
sedimentation of virions at high speeds. After washing,
to remove protein impurities and small aggregates, the
pellet was subjected to immunoaffinity purification using
an antibody against the tetraspanin CD9 to precipitate
the STING-carrying vesicles, or after removing the
HSV-1 virions with antibody against the glycoprotein D
(gD). Although this approach clearly demonstrated that
STING was in different structures from virions, co-
aggregation of virions with vesicles during ultracentrifu-
gation did not yield viral exosomes of the desired purity.
The second approach was based on dextran-10 density
gradients [111]. We sought to determine whether a linear
dextran-10 gradient (density 1.04-1.09 g/cm3) that has been
extensively used for partial purification of HSV virions could
be utilized to separate the virions from the STING-carrying
vesicles, as their densities were speculated to be different.
The results of this approach demonstrated that the two
structures were inseparable, as they were found in the same
fractions of this gradient. We believe that co-aggregation
occurring during high speed sedimentation interfered
with efficient separation of vesicles from the virions.
A third approach was the utilization of egress-deficient
HSV mutants. This approach indeed yielded STING-
carrying vesicles free of viral particles. However, whether
the composition of their cargo is the same as in wild type
virus infected cells, as largely reflected by the environment
of its origin, remains a subject of investigation.
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Having identified the limitations of commonly used
systems we developed an iodixanol gradient for separation
of vesicles from virions (Deschamps T, Kalamvoki M:
Characterization of exosomes released from HSV-1 infected
cells, in preparation) [112, 113]. The samples were obtained
from the supernatant of infected cultures following differ-
ential centrifugation at low speeds to sediment cell debris
and nuclei, filtration to remove large aggregates followed
by filter concentration. This approach resulted in segrega-
tion of any kind of HSV particles from the STING-
carrying vesicles, as was assayed by immunoblot analysis.
The HSV-1 capsid protein unique long 38 (UL38) and the
tegument protein 22 (VP22), were found in high density
fractions, while STING and the tetraspanins CD9 and
CD63 were detected in the low density fractions (Fig. 1,
panel a). Consistent with the fractionation results, a
plaque assay demonstrated that the infectious viral parti-
cles were present only in the high density fractions (Fig. 1,
panel b) (Deschamps T, Kalamvoki M: Characterization of
exosomes released from HSV-1 infected cells, in prepar-
ation). An alternative approach based on continuous
dextran-10 gradient failed to segregate the STING-
carrying vesicles from the viral particles (Fig. 1, panel c)
[111]. In conclusion, best practices to separate the HSV-
1 exosomes from HSV-1 virions involve the concentration
of cell culture supernatant by avoiding high speed sedi-
mentation, which results in aggregation.
Potential functions of exosome-like vesicles released from
herpes simplex virus infected cells
A clue to the potential functions of the virally-induced
exosomes could emerge from the analysis of their cargo.
Fig. 1 Separation of STING-carrying vesicles from HSV-1 virions. (a) Supernatant from human epithelial cells (HEp-2) infected with HSV-1(F) was
clarified by differential centrifugation to remove cell debris and nuclei, filtered concentrated before loaded onto a iodixanol gradient, as detailed
in Deschamps T. and Kalamvoki M, manuscript in preparation. Fractions were collected from the top to the bottom of the gradient and the proteins
were identified by immunoblot analysis. The tegument virion protein 22 (VP22) and the capsid unique long 38 protein (UL38) were found in high
density iodixanol fractions. STING, CD63 and CD9 were floating in the low density fractions. (b) The same fractions were tested for the presence
of infectious viral particles, by plaque assay in Vero cells. The number of viral plaques in each fraction were counted after Giemsa staining.
(c) EVs and virions derived from the supernatant of HEp-2 cells exposed to HSV-1(F) were pelleted before loaded onto a dextran-10 gradient
(1.04-1.09 g/cm3). The HSV-1 virions and the tetraspanin CD9 along with STING were found in the same fraction
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Beside STING, the tetraspanins CD63 and CD81 co-
immunoprecipitated with a CD9 antibody from the
supernatant of infected cultures, suggesting that STING
was incorporated in the tetraspanin-enriched vesicles
reminiscent to the exosomes.
In extracellular vesicles, such as exosomes, the cargo
is presumably determined by the type of signals the
donor cells communicate to the target cells. For this
reason it is not surprising that the cargo of these vesicles
can be significantly different from the parental cell
content. Additionally, despite their limited capacity it
has become clear that the miRNAs and intact transcripts
contained within these vesicles can potentially influence
gene expression in target cells. Similarly, the protein-
aceous cargo is sufficient to modulate host responses.
For example, in tumors the exosomes released by the
cancer cells facilitate tumor growth and metastasis [4, 9,
10, 114–117]. Within infected cells, pathogens modify
the cargo of exosomes to create a microenvironment
that facilitates their replication, spread and their per-
sistence in the host [5, 37, 39, 64, 71, 118, 119].
Recently, we found that the STING-carrying vesicles
released from HSV-infected cells deliver selected viral
transcripts, some of which have functions during the la-
tent stage of the virus [103]. Among those identified
were the latency associated transcript (LAT), the most
abundant non-coding RNA present in latently infected
ganglia, and viral microRNAs miR-H5, miR-H3, miR-H6
whose abundance increases during latency but rapidly
declines following herpes reactivation [103]. An
attractive hypothesis is that the virus releases these
transcripts to curtail its dissemination within the host.
By preventing the elimination of the host the virus
increases its chances to spread between individuals.
Consistent with this hypothesis is the fact that compo-
nents of the innate immunity, such as the DNA sensor
STING, are also packaged in the HSV exosomes. One
possibility is that the viral exosomes would prime neigh-
boring uninfected cells for antiviral responses, which
would subsequently control the spread of the virus.
Transcripts for immediate early viral genes, such as
the infected cell protein 27 (ICP27), and late genes, such
as the virion protein 16 (VP16), were also detected in
the viral exosomes [103]. These transcripts, provided
that are expressed, are expected to exert effects on tran-
scription. Although components of the viral exosomes
might have opposing functions it is unclear whether the
entire population of viral exosomes is homogenous and
what functions dominate under certain conditions.
Numerous studies have argued that several host
components which co-purify with HSV, HCMV, HIV-1
particles are packaged in the virions. Although such a
possibility cannot be excluded for a handful of mole-
cules, as the list of these components increases this
scenario becomes less likely. Mass spectrometric analysis
of purified HSV-1 virions have identified almost 50 host
proteins [120–122]. Notably, many of these are compo-
nents of the vesicle biogenesis and trafficking pathways.
Other studies have argued that numerous host tran-
scripts and several viral transcripts co-purify with HSV-1
and HCMV virions [123–125]. In light of our recent
studies, which demonstrated that virions and extracellu-
lar vesicles co-purify, the question arises as to whether
some of the presumed virion components may actually
belong to extracellular vesicles that co-purify with virus.
Taken together, it becomes critical to identify the viral
and host macromolecules that are packaged inside the
“HSV exosomes” and delivered to uninfected cells. This
information is important to understand the viral dissem-
ination strategies, identification of the mechanisms of
viral latency and provide insight into virus pathogenesis.
Conclusions
We have discussed a strategy that HSV-1 has evolved to
evade the host, which involves alterations in the content
of the extracellular vesicles to include components of
innate defense against DNA viruses such as STING and
selected viral gene products, such as transcripts
expressed during the latent stage of the virus. The
reorganization of the extracellular vesicles is part of the
mission of the virus to alter the environment in the
recipient cells to control its dissemination in the host.
By restricting its dissemination within the human body,
the virus ensures long-term interactions with the host and
increased chance of transmission in the population.
Cells generally secrete different types of vesicles. Our
focus has been on the STING-carrying vesicles produced
during HSV-1 infection. The components of these vesi-
cles also include three tetraspanins, CD9, CD63 and
CD81, which are usually present on the membrane of
exosomes [4, 108, 109]. For this reason and because of
their size range (50 - 110 nm) we refer to them as
“HSV-1 exosomes”. A few viral transcripts were found in
these vesicles using a targeted approach, but a more
systematic approach is in progress to identify the nucleic
acids and the proteins that constitute their cargo. In the
future it will be important to elucidate the roles of
individual factors packaged in exosomes during HSV
infection. Another issue is how the cargo composition
is determined during HSV infection. A small animal
model to address the influence of exosomes and of
individual exosomal components on HSV pathogenesis
will be invaluable.
Several pathogens have evolved mechanisms to hijack
and utilize the extracellular vesicles. Some viruses utilize
components of the exosome biogenesis machinery for
egress while others bud inside extracellular vesicles and
traffic to remote sites escaping immune surveillance.
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There are no evidence so far that herpes virions are
packaged inside exosomes. In many instances the cargo
of extracellular vesicles is modified to alter the micro-
environment of the infection [5, 32, 119].
Extracellular vesicles, including exosomes, have gar-
nered increased attention during the last decade as they
constitute a major mechanism for intercellular commu-
nication and in pathogenesis of cancer, microbial and
viral infections, autoimmune, neurodegenerative diseases
and other disease states they appear to exacerbate the
outcome of the disease. Many types of these vesicles,
including the exosomes, are stable in biological fluids,
can be transported to sites remote to the vesicular
origin, and they are characterized by unique molecular
signatures representing the physiological state of the
cells from which they originated [115, 126]. For these
reasons, their diagnostic value along with their potency
of carrying biomarkers during disease states are under
intense investigation [115, 127, 128]. These features,
along with the evolution in technologies for segregating,
purifying and characterizing the extracellular vesicles,
have intensified the research to understand their impact
in cell physiology and functions.
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